Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Clinically diagnosed cases of psoriasis Psoriasis Area Severity Index with or less than 5 percent Patients willing to sign written informed consent form and comply with the protocol
Exclusion criteria
Exclusion criteria: Pregnant and lactating women. Participants with a history or presence of renal, hepatic, or diabetes. Patients who received systemic therapy or any immunosuppressive/immunomodulatory treatment in last two months before the study except Tofacitinib Patients suffering from concomitant diseases like eczema, erysipelas, etc. Patients having secondary infection in the lesions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in PASI scoreTimepoint: Baseline, 2 weeks, 4 weeks and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Dermatology Life Quality Index (DLQI) Change in Physician s Global Assessment (PGA) Clinical photographyTimepoint: at baseline, 2 weeks, 4 weeks & 8 weeks | — |
Countries
India
Contacts
State Unani medical college and hospital